- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01274741
Present- Versus Past-focused Therapy for PTSD and Substance Use Disorder
2 maj 2019 uppdaterad av: Karen Krinsley, VA Boston Healthcare System
Pilot Study of an Integrated Exposure-Based Model for Posttraumatic Stress Disorder and Substance Use Disorder
This study compares Creating Change, a new past-focused behavioral therapy for posttraumatic stress disorder (PTSD)/substance use disorder (SUD), to Seeking Safety, an evidence-based present-focused behavioral therapy for PTSD/SUD.
Studieöversikt
Status
Avslutad
Intervention / Behandling
Detaljerad beskrivning
This study evaluates a new behavioral therapy model, Creating Change (CC) for PTSD/SUD.
CC helps clients explore the past as a step in their recovery process.
It has major public health relevance in that it is a low-cost, flexible model designed for all trauma and substance abuse types, both genders, and all clinical settings.
It has particular relevance for VA in that many veterans suffer from PTSD and SUD.
The new model demonstrated positive results in two pilot studies.
Studietyp
Interventionell
Inskrivning (Faktisk)
52
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02459
- VA Boston Healthcare System
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 65 år (Vuxen, Äldre vuxen)
Tar emot friska volontärer
Nej
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Meet Diagnostic and Statistical Manual (DSM-IV) criteria for current PTSD and current substance use disorder
- Have used a substance in the 60 days prior to intake
- Outpatient
- Plan to stay in Boston for the next 6 months
- If on psychiatric medication, are on a stable regimen for at least 4 weeks prior to participation in the study
- Have a stable mailing address and live nearby enough to come to VA Boston for treatment
- Able to sign informed consent
- Willing to participate in all assessments and urine testing
- Willing to provide a release of information for study staff to contact treaters as needed for clinical concerns
Exclusion Criteria:
- Any current acute medical condition that would either interfere with the patient's ability to attend treatment, or would be of such severity as to affect the patient's psychological functioning
- Current bipolar I disorder, schizophrenia or other psychotic disorders, mental retardation, or organic mental disorder
- Any obvious clinical sign that the patient is not sufficiently stable to participate in the treatment, or notification by the patient's primary providers that participation would be contraindicated
- Dangerousness that would present a threat to staff or patients (e.g., history of assault within the past 6 months)
- The patient is mandated to treatment
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Aktiv komparator: Seeking Safety (SS)
17 sessions of present-focused therapy Seeking Safety
|
Seeking Safety is a present-focused, evidence-based cognitive-behavioral therapy for integrated treatment of patients with PTSD/SUD.
It is a cognitive-behavioral therapy comprising 25 topics, each a coping skill relevant to both disorders.
In this study 17 of the 25 topics were conducted, one per weekly, one-hour, individual session.
|
|
Experimentell: Creating Change (CC)
17 sessions of past-focused Creating Change
|
Creating Change is a past-focused, integrated, cognitive-behavioral therapy for PTSD/SUD.
It has 17 topics, which in this study were delivered in weekly one-hour sessions, in individual format.
The treatment explores how PTSD and SUD arose and interacted across the patient's life, including constructing a narrative of its meaning, processing associated emotions and memories, and exploring themes related to these.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in PTSD Checklist total score - from baseline through end of treatment and 3-month followup
Tidsram: Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
PTSD symptoms assessed via self-report measure
|
Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
|
Change in diagnosis of PTSD on the MINI Neuropsychiatric Interview - from baseline through end of treatment and 3-month followup
Tidsram: Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
PTSD diagnosis as assessed by a trained interviewer
|
Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
|
Change in Addiction Severity Index alcohol composite score - from baseline through end of treatment and 3-month followup
Tidsram: Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
Alcohol use and associated problems as measured by blinded-interviewer measure Composite.
These outcome variables will be measured at baseline, end of treatment and 3-month followup.
|
Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
|
Change in Addiction Severity Index drug composite score - from baseline through end of treatment and 3-month followup
Tidsram: Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
Drug use and associated problems as measured by blinded-interviewer measure Composite.
These outcome variables will be measured at baseline, end of treatment and 3-month followup.
Urinanlysis/breathalyzer will be obtained to verify ASI self-report.
|
Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Change in Quality of Life Satisfaction & Enjoyment Scale - from baseline through end of treatment and 3-month followup
Tidsram: Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
Self-report measure
|
Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
|
Change in Brief Symptom Inventory-Global Severity Index - from baseline through end of treatment and 3-month followup
Tidsram: Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
Self-report measure
|
Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
|
Change in Beliefs About Substance Use - from baseline through end of treatment and 3-month followup
Tidsram: Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
Self-report measure
|
Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
|
Change in General Self-Efficacy - from baseline through end of treatment and 3-month followup: Self-report measure
Tidsram: Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
Self-report measure
|
Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
|
Change in Coping Self-Efficacy Scale - from baseline through end of treatment and 3-month followup
Tidsram: Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
Self-report measure
|
Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
|
Change in World Assumptions Scale - from baseline through end of treatment and 3-month followup
Tidsram: Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
Self-report measure
|
Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
|
Change in Trauma Related Guilt Inventory - from baseline through end of treatment and 3-month followup
Tidsram: Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
Self-report measure
|
Baseline, end of treatment (approximately 4 months from baseline), and 3-month followup
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Karen E. Krinsley, Ph.D., VA Boston Healthcare System
- Huvudutredare: Lisa M Najavits, PhD, VA Boston Healthcare System
Publikationer och användbara länkar
Den som ansvarar för att lägga in information om studien tillhandahåller frivilligt dessa publikationer. Dessa kan handla om allt som har med studien att göra.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 januari 2011
Primärt slutförande (Faktisk)
1 mars 2015
Avslutad studie (Faktisk)
1 mars 2015
Studieregistreringsdatum
Först inskickad
10 januari 2011
Först inskickad som uppfyllde QC-kriterierna
10 januari 2011
Första postat (Uppskatta)
11 januari 2011
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
3 maj 2019
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
2 maj 2019
Senast verifierad
1 maj 2019
Mer information
Termer relaterade till denna studie
Nyckelord
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- SPLA-CX000308-01 (VA CSRD)
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
NEJ
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .